Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Fate Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing off-the-shelf, induced pluripotent stem cell (iPSC)-derived cellular immunotherapies. The company operates within the biotechnology and cell therapy industries, with a primary emphasis on oncology and immune-mediated diseases. Its core value proposition centers on creating standardized, scalable immune cell products designed to overcome limitations of patient-specific (autologous) cell therapies.
The company’s primary business lines involve the research and development of iPSC-derived natural killer (NK) cell and T-cell therapies, which are engineered for enhanced anti-tumor activity, persistence, and safety. Fate Therapeutics primarily serves oncology patients and clinical research partners, positioning itself as a pioneer in iPSC-based immuno-oncology platforms. Founded in 2007, the company evolved from an academic discovery platform into a publicly traded biotechnology company, completing its initial public offering in 2013 and advancing multiple programs into clinical development.
Business Operations
Fate Therapeutics operates through a single reportable segment focused on the discovery, development, and potential commercialization of cellular immunotherapies. Its operations are centered on proprietary iPSC Platform technologies that enable the creation of clonal master cell banks, which are then differentiated into uniform immune effector cells. Revenue generation to date has primarily consisted of collaboration payments and research funding rather than product sales, as no therapies have yet received regulatory approval.
The company conducts research, manufacturing, and early-stage clinical development primarily in the United States, with integrated capabilities spanning cell engineering, process development, and clinical supply manufacturing. Key assets include internally developed gene-editing technologies and controlled manufacturing processes. Fate Therapeutics has historically entered into strategic collaborations, including research and development partnerships with large pharmaceutical companies, though some prior alliances have concluded as programs progressed or strategies shifted.
Strategic Position & Investments
Fate Therapeutics’ strategic direction emphasizes advancing off-the-shelf cell therapies that can be manufactured at scale and delivered without patient-specific customization. Growth initiatives have focused on expanding and refining its iPSC-derived NK and T-cell pipelines, incorporating multiplex gene editing to enhance persistence, targeting, and resistance to immunosuppressive tumor environments.
The company has made significant investments in internal manufacturing infrastructure and process development to support clinical and potential commercial supply. Rather than pursuing a diversified portfolio of subsidiaries, Fate Therapeutics concentrates investment within its wholly owned pipeline programs. Emerging areas of focus include combination strategies with other immuno-oncology agents and next-generation cell designs intended to improve durability and clinical outcomes.
Geographic Footprint
Fate Therapeutics is headquartered in San Diego, California, which serves as the central hub for its research, development, and corporate operations. The company’s activities are primarily concentrated in North America, where it conducts clinical trials, manufacturing, and regulatory interactions.
While Fate Therapeutics does not maintain extensive international operations, its clinical programs have included trial sites and regulatory engagement in select international markets, reflecting a broader global development strategy. The company’s intellectual property and scientific influence extend internationally through published research, patent filings, and prior global collaborations.
Leadership & Governance
Fate Therapeutics is led by an experienced executive team with backgrounds in biotechnology, pharmaceuticals, and translational science. The leadership emphasizes disciplined capital allocation, scientific rigor, and the long-term development of scalable cell therapy platforms as the foundation of corporate strategy.
Key executives include:
- Paul J. Hastings, Ph.D. – Chief Executive Officer
- Bob Valamehr, Ph.D. – President of Research and Development
- Juan Carlos Jauregui, M.D. – Chief Medical Officer
- Scott Wolchko – Chief Financial Officer
- Rick Klausner, M.D. – Board Chair and Director
The governance structure includes a board of directors with expertise in oncology, cell therapy, finance, and public company oversight, supporting the company’s focus on clinical execution and long-term value creation.